White Pine Investment CO boosted its stake in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 3.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,738 shares of the medical research company’s stock after purchasing an additional 860 shares during the quarter. Laboratory Corp. of America comprises 2.0% of White Pine Investment CO’s holdings, making the stock its 25th largest holding. White Pine Investment CO’s holdings in Laboratory Corp. of America were worth $3,937,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of LH. Hudock Capital Group LLC lifted its holdings in shares of Laboratory Corp. of America by 17.9% during the first quarter. Hudock Capital Group LLC now owns 592 shares of the medical research company’s stock worth $90,000 after purchasing an additional 90 shares during the period. Brinker Capital Inc. lifted its holdings in shares of Laboratory Corp. of America by 12.9% during the first quarter. Brinker Capital Inc. now owns 5,656 shares of the medical research company’s stock worth $865,000 after purchasing an additional 647 shares during the period. Hanson & Doremus Investment Management raised its position in Laboratory Corp. of America by 646.3% during the first quarter. Hanson & Doremus Investment Management now owns 709 shares of the medical research company’s stock valued at $108,000 after acquiring an additional 614 shares in the last quarter. Smith Graham & Co. Investment Advisors LP raised its position in Laboratory Corp. of America by 1.1% during the first quarter. Smith Graham & Co. Investment Advisors LP now owns 28,100 shares of the medical research company’s stock valued at $4,299,000 after acquiring an additional 300 shares in the last quarter. Finally, Eukles Asset Management raised its position in Laboratory Corp. of America by 0.5% during the first quarter. Eukles Asset Management now owns 14,803 shares of the medical research company’s stock valued at $2,265,000 after acquiring an additional 79 shares in the last quarter. 91.51% of the stock is currently owned by institutional investors.

In other news, Director R Sanders Williams sold 1,038 shares of the company’s stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $147.00, for a total value of $152,586.00. Following the transaction, the director now owns 8,924 shares of the company’s stock, valued at approximately $1,311,828. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.74% of the company’s stock.

Several brokerages recently weighed in on LH. ValuEngine cut Laboratory Corp. of America from a “hold” rating to a “sell” rating in a research report on Thursday, April 18th. Zacks Investment Research cut Laboratory Corp. of America from a “hold” rating to a “sell” rating in a research report on Tuesday, January 8th. Barclays boosted their price objective on Laboratory Corp. of America from $165.00 to $173.00 and gave the company an “overweight” rating in a research report on Monday, March 18th. TheStreet cut Laboratory Corp. of America from a “b-” rating to a “c+” rating in a research report on Friday, January 11th. Finally, Jefferies Financial Group upgraded Laboratory Corp. of America from a “hold” rating to a “buy” rating and boosted their price target for the stock from $154.00 to $190.00 in a research report on Tuesday, April 2nd. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company’s stock. Laboratory Corp. of America currently has an average rating of “Hold” and a consensus target price of $175.50.

NYSE LH traded up $7.04 on Tuesday, reaching $151.29. 1,122,410 shares of the company were exchanged, compared to its average volume of 824,513. The firm has a market capitalization of $14.43 billion, a P/E ratio of 13.73, a price-to-earnings-growth ratio of 1.48 and a beta of 1.15. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.51. Laboratory Corp. of America Holdings has a fifty-two week low of $119.38 and a fifty-two week high of $190.35.

Laboratory Corp. of America (NYSE:LH) last announced its quarterly earnings results on Thursday, February 7th. The medical research company reported $2.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.48 by $0.04. Laboratory Corp. of America had a return on equity of 17.05% and a net margin of 8.43%. The business had revenue of $2.79 billion for the quarter, compared to analyst estimates of $2.78 billion. During the same quarter in the prior year, the company posted $2.45 EPS. The company’s quarterly revenue was up 1.6% on a year-over-year basis. As a group, sell-side analysts forecast that Laboratory Corp. of America Holdings will post 11.22 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://theolympiareport.com/2019/04/23/white-pine-investment-co-buys-860-shares-of-laboratory-corp-of-america-holdings-lh.html.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Featured Article: Why are percentage gainers important?

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.